BioNTech Other Current Liab from 2010 to 2024
BNTX Stock | USD 94.10 2.85 2.94% |
Other Current Liabilities | First Reported 2018-12-31 | Previous Quarter 1.3 B | Current Value 914.6 M | Quarterly Volatility 1.4 B |
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech main balance sheet or income statement drivers, such as Tax Provision of 243 M, Net Interest Income of 367.2 M or Interest Income of 375.5 M, as well as many exotic indicators such as Price To Sales Ratio of 5.71, Dividend Yield of 0.0113 or PTB Ratio of 1.19. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
BioNTech | Other Current Liab |
Latest BioNTech's Other Current Liab Growth Pattern
Below is the plot of the Other Current Liab of BioNTech SE over the last few years. It is BioNTech's Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.
Other Current Liab | 10 Years Trend |
|
Other Current Liab |
Timeline |
BioNTech Other Current Liab Regression Statistics
Arithmetic Mean | 545,945,723 | |
Geometric Mean | 56,652,146 | |
Coefficient Of Variation | 184.70 | |
Mean Deviation | 768,950,393 | |
Median | 13,913,000 | |
Standard Deviation | 1,008,341,997 | |
Sample Variance | 1016753.6T | |
Range | 3B | |
R-Value | 0.63 | |
Mean Square Error | 655157.2T | |
R-Squared | 0.40 | |
Significance | 0.01 | |
Slope | 142,897,392 | |
Total Sum of Squares | 14234550.2T |
BioNTech Other Current Liab History
About BioNTech Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include BioNTech income statement, its balance sheet, and the statement of cash flows. BioNTech investors use historical funamental indicators, such as BioNTech's Other Current Liab, to determine how well the company is positioned to perform in the future. Although BioNTech investors may use each financial statement separately, they are all related. The changes in BioNTech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BioNTech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on BioNTech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in BioNTech. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Other Current Liabilities | 1.3 B | 979.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:Check out the analysis of BioNTech Correlation against competitors. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is BioNTech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNTech. If investors know BioNTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share 0.5 | Revenue Per Share 11.369 | Quarterly Revenue Growth (0.85) | Return On Assets (0.01) |
The market value of BioNTech SE is measured differently than its book value, which is the value of BioNTech that is recorded on the company's balance sheet. Investors also form their own opinion of BioNTech's value that differs from its market value or its book value, called intrinsic value, which is BioNTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNTech's market value can be influenced by many factors that don't directly affect BioNTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.